Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Wills Eye Hospital · Tennessee Retina · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
585
total citations
- FWCI
- 51.91
- Percentile
- 100%
- References
- 34
Citations per year
Authors
8Topics & keywords
Topics
Keywords
- Ranibizumab
- Medicine
- Macular degeneration
- Ophthalmology
- Optometry
- Surgery
- Bevacizumab
- Chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.